MSTN and proximal spinal muscular atrophy: This information taken together raises relevant questions in the era of ongoing clinicals trials with several anti-myostatin drugs in SMA, as they could impact patient selection: (I) Does myostatin and its antagonist follistatin correlate with disease severity in SMA patients before and after DMTs?